What is the use of artesunate injection 120mg?
Pharmaceutical Product Monograph: Artesunate Injection (120 mg)
In the pharmaceutical industry, Artesunate is a semi-synthetic derivative of artemisinin, a sesquiterpene lactone. As a pharmacist and manufacturer, I view this molecule as the “Gold Standard Antimalarial”—it is technically the first-line treatment for Severe and Complicated Malaria as per WHO 2026 Guidelines, significantly outperforming older treatments like Quinine in terms of survival rates.
At your WHO-GMP facility in Mumbai, Artesunate 120 mg is a high-impact “Life-Saving” SKU. It is specifically dosed for adult patients or older children to provide rapid clearance of parasites from the bloodstream.
Therapeutic Profile: Primary Indications
Artesunate 120 mg is strictly reserved for patients who cannot take oral medications due to the severity of their infection.
| Indication | Clinical Context | Technical Rationale |
| Severe Malaria | P. falciparum Infection | Used when there are signs of organ dysfunction (e.g., kidney failure, jaundice) or high parasite density. |
| Cerebral Malaria | Neurological Crisis | Rapidly crosses the blood-brain barrier to stop the parasite-induced “sludging” of red blood cells in the brain. |
| Pernicious Malaria | Multi-organ Failure | Vital for patients with severe anemia, respiratory distress, or persistent vomiting. |
| Initial Treatment | Emergency Stabilization | Administered as a “loading dose” before transitioning to Oral Artemisinin-based Combination Therapy (ACT). |
Mechanism: Endoperoxide Bridge Activation
Artesunate works by “bombing” the parasite from within the red blood cell:
Heme Activation: When the drug enters a malaria-infected red blood cell, it reacts with the iron (heme) released by the parasite’s digestion of hemoglobin.
Free Radical Generation: This reaction breaks the drug’s endoperoxide bridge, creating highly reactive “free radicals.”
Molecular Destruction: These radicals attack and damage the parasite’s proteins and membranes, leading to rapid death across almost all stages of the parasite’s life cycle.
The Pharmacist’s “Technical Warning”
The “PADAM” Risk: As a pharmacist, I must highlight a technical side effect called Post-Artesunate Delayed Hemolysis (PADAM). Some patients may experience a drop in hemoglobin 1 to 3 weeks after treatment. Monitoring is required post-discharge.
Reconstitution Protocol: Artesunate is unstable in liquid form. It is supplied as a dry powder with two separate ampoules: a Sodium Bicarbonate solvent (to dissolve) and a Sodium Chloride diluent (to thin for injection).
Immediate Use: Once reconstituted, the solution must be used within 1 hour. If it appears cloudy or contains particles, it must be discarded.
Transition to ACT: WHO protocols dictate that once the patient can swallow, a full 3-day course of an Oral ACT (like Artemether-Lumefantrine) must be completed to prevent resistance.
The Manufacturer’s Perspective: Technical & Export
From a production and B2B standpoint at your facility in Mumbai:
The “Triple-Pack” USP: On your digital marketplace, highlight your Comprehensive Injection Kit. Providing the 120 mg vial, the Bicarbonate ampoule, and the Saline ampoule in a single blister is a major technical advantage for international tenders (e.g., Global Fund, USAID).
Stability for Export: Artesunate powder is sensitive to high temperatures. Your WHO-PQ (Pre-qualification) standards and moisture-resistant sealing ensure a 24-month shelf life in the humid Zone IVb tropical regions of Africa and SE Asia.
Dossier Support: We provide full WHO-standard CTD/eCTD Dossiers to support your firm’s registration in international B2B tenders for infectious disease and tropical medicine.